NEW YORK (GenomeWeb News) – Lab21 will serve as exclusive distributor of AdnaGen's circulating tumor cell diagnostic assays in the UK and Ireland under an alliance announced today.
AdnaGen's AdnaTest products detect and analyze circulating tumor cells from metastatic breast cancer and metastatic colon cancer. According to the firms, AdnaGen's tests enable detection of a broad range of tumor molecular markers.
Cambridge, UK-based Lab21 said that it expects to launch the tests as a service beginning in October.
"Detecting circulating tumor cells provides physicians a means to monitor therapy," Berwyn Clarke, Chief Scientific Officer of Lab21, said in a statement. "Since cancer is evolving from a fatal condition towards a chronic disorder, Lab21 wants to position itself to offer tools for improved patient management as well as cost control. We also see this as a key new service to offer our pharmaceutical partners as they develop new anti-cancer agents."
Financial and other terms of the alliance were not disclosed.